当前位置: 首页 > 期刊 > 《中国当代医药》 > 2011年第16期 > 正文
编号:12090246
促红细胞生成素防治早产儿贫血的临床观察(1)
http://www.100md.com 2011年6月5日 侯淑萍
第1页

    参见附件(1938KB,2页)。

     [摘要] 目的:观察重组人促红细胞生成素(rhEPO)防治早产儿贫血的临床效果。方法:将96例早产儿(胎龄30~35周)随机分为观察组和对照组各48例。对照组给予常规治疗;观察组除常规治疗外,从出生第7天开始给予rhEPO 250 IU/(kg·次),隔日1次,每周3次,皮下注射,共用药4周,必要时输血。分别检测用药前、用药后4周血常规红细胞(RBC)、血红蛋白(Hb)、红细胞压积(HCT)、网织红细胞(Ret)等指标的变化。结果:两组血常规各项指标进行对比分析,观察组与对照组比较,差异有统计学意义(P<0.05)。观察组输血发生率显著低于对照组(P<0.05)(观察组为16.7%,对照组为39.6%)。结论:促红细胞生成素防治早产儿贫血效果明显,可减少输血次数。

    [关键词] 促红细胞生成素;早产儿;贫血;临床观察

    [中图分类号] R722 [文献标识码]A[文章编号]1674-4721(2011)06(a)-028-02

    Erythropoietin in anemia prevention and control clinical observation of premature children

    HOU Shuping

    Department of Pediatrics, Puyang City Oil Field General Hospital, Henan Province, Puyang 457001, China

    [Abstract] Objective: To observe the recombinant human erythropoietin (rhEPO) control the clinical effects of anemia in premature children. Methods: 96 preterm children (gestational age 30 to 35 weeks) were randomly divided into two groups and the control group of 48 cases. The control group received conventional therapy; observation group in addition to conventional treatment, the 7th day from birth to give rhEPO 250 IU/(kg·time), every other day for 1, 3 times a week, administered subcutaneously 4 weeks, if necessary, blood transfusions. Detected before treatment, 4 weeks after treatment blood red blood cell (RBC), hemoglobin (Hb), hematocrit (HCT), reticulocytes (Ret) and other indicators of change. Results: Both groups were analyzed blood indicators was observed compared with the control group, the difference was statistically significant (P<0.05). Transfusion observation group were significantly lower than the control group (P<0.05) (16.7% in the observation group and control group 39.6%). Conclusion: Control of erythropoietin effect is anemia in preterm children, can reduce the number of transfusions.

    [Key words] Erythropoietin; Premature child; Anemia; Clinical observation

    早产儿贫血是临床常见疾病,贫血对早产儿的智力、体格发育及免疫功能等均有一定影响。笔者应用重组人促红细胞生成素(rhEPO)防治早产儿贫血,取得满意疗效,现报道如下:

    1 资料与方法

    1.1 一般资料

    选取2008年1月~2010年12月在新生儿病房住院的早产儿共96例。入选标准:胎龄30~35周,血常规检查血红蛋白(Hb)在160~190 g/L。将其随机分为观察组和对照组,每组各48例。所有患儿均排除严重感染、持续出血、机械通气、长期禁食、先天畸形及血液系统疾病等 ......

您现在查看是摘要介绍页,详见PDF附件(1938KB,2页)